Improved treatment technology in the fight against prostate cancer is used directly in an ongoing clinical trial
The collaboration between SpectraCure and the German company MedCom GmbH has reached a stage where the technology will be used in SpectraCure's ongoing clinical study. The technology leads to increased precision, accuracy and safety in the treatment of recurrent prostate cancer. SpectraCure runs an EU-funded development project, together with MedCom GmbH. The purpose of the […]
SpectraCure presentations at investor meetings this fall
SpectraCure (http://www.spectcomracure.) will be presented at Småbolagsjakten Live, September 25th and at at Stora Aktiedagen, November 4th. SpectraCure will be presented at Småbolagsjakten Live, September 25th Welcome to come and listen when the CEO of SpectraCure, Masoud Khayyami, holds a company presentation at the investor meeting Småbolagsjakten Live.The event has attracted great interest and is already sold […]
SpectraCure strengthens the organization with a PR Manager
September 1st, 2019 Annika Andersson will start as PR Manager at SpectraCure. Annika has a long experience of public relations, media and communication both strategically and operationally and has for the past 16 years run a communication agency. Annika contributes with expertise, experience and commitment. – The new role is also an important strengthening to […]
SpectraCures new generation P18
SpectraCure’s current main focus are the clinical phase 2 study and the development of the new generation of SpectraCure's treatment system. The clinical trial, designated for treatment of patients with recurrent prostate cancer using the company's photodynamic therapy (PDT) technology, is ongoing at our partner hospitals. The recruitment of patients for the fall in the […]
Great attention for SpectraCure in Boston
SpectraCure received a lot of attention around its clinical study results at the World Conference in Boston, attended by world leading clinical researchers. On Wednesday, July 3rd, SpectraCure presented results from the company's phase 1 study at the 17th International Photodynamic Association World Congress in Boston, USA. Johannes Swartling, CTO of SpectraCure held the presentation […]
SpectraCure reports positive results from the company’s clinical phase 1-study
Today July 2nd, 2019, SpectraCure AB ("Spec") reports positive results and good clinical effects regarding safety in the company's clinical phase 1-study of patients with recurrent prostate cancer. SpectraCure has conducted a clinical phase 1-study on treatment of patients with recurrent prostate cancer with the company's photodynamic therapy (PDT) technology. A total of 11 patients […]
SpectraCure presents results from Phase 1 study
SpectraCure presents results from the company's Phase 1 study at The 17th International Photodynamic Association World Congress in Boston. SpectraCure (publ) will present results from the company's Phase 1 study at the International Photodynamic Association World Congress arranged June 28th – July 4th in Boston, Massachusetts, USA. The presentation will be held by Johannes Swartling, […]
Preliminary results from SpectraCure’s prostate treatments
Preliminary results have been reported from the latest patient treatments in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. A very clear treatment effect is seen on MR images in the treatment area, indicating destruction of the tumour, just like previously treated patients with the high […]
New patient treatment, phase 2 initiated
A patient was treated on Tuesday April 9th, 2019, in SpectraCure's clinical trial for the treatment of patients with recurrent prostate cancer, at University College London Hospital. The treatment was performed with SpectraCure's photodynamic therapy (PDT) method. The procedure went as expected and the patient is doing well. "It is gratifying that we are now […]
SpectraCure files for a new patent
SpectraCure has filed for a new patent to the European Patent Office, the patent covers a new technology to improve the company's IDOSE technology. The IDOSE technique is at the heart of the company's method of treating prostate cancer with photodynamic therapy (PDT). In short, the technique implies that the prostate tissue is monitored during […]
